Comparison of josamycin and erythromycin in the therapy of Mycoplasma pneumoniae pneumonia. 1976

R P Wenzel, and J O Hendley, and W K Dodd, and J M Gwaltney

A controlled, double-blind study was performed to compare the efficacy of two macrolide antibiotics, erythromycin and josamycin, in the therapy of Mycoplasma pneumoniae pneumonia. Marine Corps recruit volunteers received one of the two antibiotics in a dosage of 2 g daily for 7 days. Twelve of 21 men treated with josamycin and 9 of 25 men treated with erythromycin had confirmed M. pneumoniae pneumonia. The josamycin-treated group remained hospitalized for 5.4 +/- 1.2 days compared to 5.1 +/- 2.0 days for the erythromycin-treated group (0.60 > P > 0.50). Fever days were similar for the josamycin-treated (1.4 +/- 0.4) and erythromycin-treated (1.2 +/- 0.3) groups (P = 0.95). There was no difference in resolution of signs and symptoms of illness in the two study populations. Thus, josamycin is as efficacious as erythromycin in the therapy of M. pneumoniae pneumonia.

UI MeSH Term Description Entries
D007933 Leucomycins An antibiotic complex produced by Streptomyces kitasatoensis. The complex consists of a mixture of at least eight biologically active components, A1 and A3 to A9. Leucomycins have both antibacterial and antimycoplasmal activities.
D009175 Mycoplasma Infections Infections with species of the genus MYCOPLASMA. Eperythrozoonosis,Infections, Mycoplasma,Eperythrozoonoses,Infection, Mycoplasma,Mycoplasma Infection
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

R P Wenzel, and J O Hendley, and W K Dodd, and J M Gwaltney
January 1965, Antimicrobial agents and chemotherapy,
R P Wenzel, and J O Hendley, and W K Dodd, and J M Gwaltney
April 1980, Scottish medical journal,
R P Wenzel, and J O Hendley, and W K Dodd, and J M Gwaltney
March 2001, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
R P Wenzel, and J O Hendley, and W K Dodd, and J M Gwaltney
May 1967, The New England journal of medicine,
R P Wenzel, and J O Hendley, and W K Dodd, and J M Gwaltney
November 2000, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
R P Wenzel, and J O Hendley, and W K Dodd, and J M Gwaltney
January 2005, Journal of computer assisted tomography,
R P Wenzel, and J O Hendley, and W K Dodd, and J M Gwaltney
January 2020, Pakistan journal of medical sciences,
R P Wenzel, and J O Hendley, and W K Dodd, and J M Gwaltney
March 1968, IMJ. Illinois medical journal,
R P Wenzel, and J O Hendley, and W K Dodd, and J M Gwaltney
January 1971, Military medicine,
R P Wenzel, and J O Hendley, and W K Dodd, and J M Gwaltney
February 2003, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!